{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:10:38Z","timestamp":1790878238891,"version":"4.1.0"},"reference-count":63,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>In both the early and advanced settings, cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors are approved for use in hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative (HER2\u2013) breast cancer (BC) in combination with endocrine therapy and increase the duration of invasive disease-free survival and progression-free survival (PFS). The duration of response to these treatments is variable between individual patients, supporting the use of biomarkers to inform treatment. Here, we investigated plasma thymidine kinase activity (TKa) as a continuous prognostic and predictive biomarker of response to CDK4\/6 inhibitor\u2013based therapy in early and advanced hormone receptor\u2013positive\/HER2\u2013 BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      TKa levels were assessed longitudinally at baseline, on treatment, and post-treatment on plasma samples from 80 metastatic and 28 high-risk patients receiving CDK4\/6 inhibitor\u2013based therapy as the standard of care. Patients were enrolled in the prospective observational Roswell Park Ciclib Study (ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04526587\">NCT04526587<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      In the metastatic setting, TKa levels in baseline samples were inversely associated with the duration of PFS (hazard ratio, 1.91,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .03). There was also a reduction in TKa levels from baseline to on-treatment in metastatic disease that displayed longer PFS (\u226520 months; 120.7 DiviTum units of activity, DuA\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      30.6 DuA,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .028). Individuals with metastatic disease that displayed shorter PFS (\u22648 months) presented with higher TKa values on treatment (220.2 DuA\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      30.6 DuA,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .008) compared with patients with longer PFS. In early-stage high-risk cases, TKa values were lower on treatment compared with baseline (41.4 DuA\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      114.8 DuA,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 3.55e-08).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>These findings support further investigation of circulating TKa levels as a continuous prognostic and predictive biomarker of response to CDK4\/6 inhibitor\u2013based therapy. Future studies are well-suited to assess definitive TKa cutoff values to inform treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-00346","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:59:16Z","timestamp":1769201956000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4\/6 Inhibitors"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6965-0704","authenticated-orcid":true,"given":"Thomas N.","family":"O'Connor","sequence":"first","affiliation":[{"name":"Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-0609","authenticated-orcid":true,"given":"Emily","family":"Schultz","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-7103","authenticated-orcid":true,"given":"Sheheryar","family":"Kabraji","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2300-0524","authenticated-orcid":true,"given":"Ellis","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Williams","sequence":"additional","affiliation":[{"name":"Biovica International AB, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-5969","authenticated-orcid":true,"given":"Erik S.","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka K.","family":"Witkiewicz","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn233"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy192"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-05125-4"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13555"},{"key":"e_1_3_10_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00666"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00438-0"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03308-0"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514"},{"key":"e_1_3_10_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01994"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.015"},{"key":"e_1_3_10_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488"},{"key":"e_1_3_10_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00886"},{"key":"e_1_3_10_26_2","first-page":"2027","article-title":"Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs","volume":"44","author":"Schwartz JL","year":"2003","unstructured":"Schwartz JL, Tamura Y, Jordan R, et al: Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 44:2027-2032, 2003","journal-title":"J Nucl Med"},{"key":"e_1_3_10_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406332102"},{"key":"e_1_3_10_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03515-x"},{"key":"e_1_3_10_29_2","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-2010-0148"},{"key":"e_1_3_10_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-016-5024-z"},{"key":"e_1_3_10_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24335"},{"key":"e_1_3_10_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.10.010"},{"key":"e_1_3_10_33_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2012-0162"},{"key":"e_1_3_10_34_2","first-page":"1791","article-title":"Serum thymidine kinase 1 activity following nephrectomy for renal cell carcinoma and radiofrequency ablation of metastases to lung and liver","volume":"36","author":"Nisman B","year":"2016","unstructured":"Nisman B, Appelbaum L, Yutkin V, et al: Serum thymidine kinase 1 activity following nephrectomy for renal cell carcinoma and radiofrequency ablation of metastases to lung and liver. Anticancer Res 36:1791-1797, 2016","journal-title":"Anticancer Res"},{"key":"e_1_3_10_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000276"},{"key":"e_1_3_10_36_2","first-page":"1321","article-title":"Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia","volume":"70","author":"Stelmach P","year":"2016","unstructured":"Stelmach P, B\u0142o\u0144ski JZ, Wawrzyniak E, et al: Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia. Postepy Hig Med Dosw (Online) 70:1321-1330, 2016","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"e_1_3_10_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030702"},{"key":"e_1_3_10_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000966"},{"key":"e_1_3_10_39_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.654339"},{"key":"e_1_3_10_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0913-7"},{"key":"e_1_3_10_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/1354750X.2023.2168063"},{"key":"e_1_3_10_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2579-x"},{"key":"e_1_3_10_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00399-w"},{"key":"e_1_3_10_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61416-1"},{"key":"e_1_3_10_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.03.001"},{"key":"e_1_3_10_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.04.002"},{"key":"e_1_3_10_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1562"},{"key":"e_1_3_10_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.12.030"},{"key":"e_1_3_10_49_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24700"},{"key":"e_1_3_10_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01334-2"},{"key":"e_1_3_10_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3271"},{"key":"e_1_3_10_52_2","unstructured":"Biovica Inc: DiviTum TKa Test Requisition 2023. https:\/\/divitum.com\/wp-content\/uploads\/2023\/09\/divitum-trf-1016-sep2023-final2.pdf"},{"key":"e_1_3_10_53_2","unstructured":"U.S. Food & Drug Administration: 510(k) Substantial equivalence determination decision summary assay only 2022. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K202852.pdf"},{"key":"e_1_3_10_54_2","unstructured":"Reference deleted"},{"key":"e_1_3_10_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji237"},{"key":"e_1_3_10_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.011"},{"key":"e_1_3_10_57_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1390"},{"key":"e_1_3_10_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30804-6"},{"key":"e_1_3_10_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104103"},{"key":"e_1_3_10_60_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2607"},{"key":"e_1_3_10_61_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174455"},{"key":"e_1_3_10_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.352"},{"key":"e_1_3_10_63_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P1-09-06"},{"key":"e_1_3_10_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.1012"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-00346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:47:41Z","timestamp":1772812061000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-00346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1200\/PO-25-00346"],"URL":"https:\/\/doi.org\/10.1200\/po-25-00346","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500346"}}